These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 11367188)

  • 61. Effects of Food and Drug Administration warnings on antidepressant use in a national sample.
    Olfson M; Marcus SC; Druss BG
    Arch Gen Psychiatry; 2008 Jan; 65(1):94-101. PubMed ID: 18180433
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Safety monitoring of drugs granted exclusivity under the Best Pharmaceuticals for Children Act: what the FDA has learned.
    Mathis LL; Iyasu S
    Clin Pharmacol Ther; 2007 Aug; 82(2):133-4. PubMed ID: 17632537
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Current sunscreen issues: 2007 Food and Drug Administration sunscreen labelling recommendations and combination sunscreen/insect repellent products.
    Hexsel CL; Bangert SD; Hebert AA; Lim HW
    J Am Acad Dermatol; 2008 Aug; 59(2):316-23. PubMed ID: 18485529
    [TBL] [Abstract][Full Text] [Related]  

  • 64. New drug and biological drug products; evidence needed to demonstrate effectiveness of new drugs when human efficacy studies are not ethical or feasible. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2002 May; 67(105):37988-98. PubMed ID: 12049094
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Drugs and biologics in pregnancy and breastfeeding: FDA in the 21st century.
    Kweder SL
    Birth Defects Res A Clin Mol Teratol; 2008 Sep; 82(9):605-9. PubMed ID: 18704917
    [No Abstract]   [Full Text] [Related]  

  • 66. Drug testing in children.
    Greene J
    FDA Consum; 1978 Jun; 12(5):11-3. PubMed ID: 10308116
    [TBL] [Abstract][Full Text] [Related]  

  • 67. The march toward rational therapeutics in children.
    Gorman RL
    Pediatr Infect Dis J; 2003 Dec; 22(12):1119-23. PubMed ID: 14688584
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Vaccine INDs: review of clinical holds.
    Miller DL; Ross JJ
    Vaccine; 2005 Jan; 23(9):1099-101. PubMed ID: 15629351
    [TBL] [Abstract][Full Text] [Related]  

  • 69. FDA proposes that patient package insert program be rescinded.
    Hospitals; 1982 Feb; 56(4):84. PubMed ID: 7054117
    [No Abstract]   [Full Text] [Related]  

  • 70. PDA response. FDA advance notice of proposed rulemaking on electronic identification/signatures. Parenteral Drug Association.
    J Parenter Sci Technol; 1993; 47(1):4-8. PubMed ID: 8445499
    [No Abstract]   [Full Text] [Related]  

  • 71. FDA gene rules impractical.
    Morrison C
    Nat Biotechnol; 2001 Jan; 19(1):5. PubMed ID: 11135515
    [No Abstract]   [Full Text] [Related]  

  • 72. CDC and FDA response to risk of confusion in dosing Tamiflu oral suspension.
    Budnitz DS; Lewis LL; Shehab N; Birnkrant D
    N Engl J Med; 2009 Nov; 361(19):1913-4. PubMed ID: 19797275
    [No Abstract]   [Full Text] [Related]  

  • 73. Therapeutic orphans: who speaks for children?
    Shirkey HC
    South Med J; 1970 Nov; 63(11):1361-3. PubMed ID: 5475304
    [No Abstract]   [Full Text] [Related]  

  • 74. Recommendations for the labeling of large volume parenterals. National Coordinating Committee on Large Volume Parenterals.
    Am J Hosp Pharm; 1978 Jan; 35(1):49-51. PubMed ID: 623118
    [TBL] [Abstract][Full Text] [Related]  

  • 75. FDA clears drug trials to combat systemic CMV.
    AIDS Patient Care STDS; 1997 Aug; 11(4):295-6. PubMed ID: 11361854
    [No Abstract]   [Full Text] [Related]  

  • 76. Boxed warnings and other FDA communication tools.
    Marks NS; Weiss K
    Am Fam Physician; 2010 Feb; 81(3):259. PubMed ID: 20112882
    [No Abstract]   [Full Text] [Related]  

  • 77. Assessment and reporting of clinical pharmacology information in drug labeling.
    Spyker DA; Harvey ED; Harvey BE; Harvey AM; Rumack BH; Peck CC; Atkinson AJ; Woosley RL; Abernethy DR; Cantilena LR
    Clin Pharmacol Ther; 2000 Mar; 67(3):196-200. PubMed ID: 10741621
    [No Abstract]   [Full Text] [Related]  

  • 78. Investigation of new drugs--FDA guidelines and perspectives of drug innovations.
    Psychopharmacol Bull; 1972 Apr; 8(2):16-31. PubMed ID: 4550365
    [No Abstract]   [Full Text] [Related]  

  • 79. FDA problems with medications in the marketplace: III. 'Therapeutic orphans'.
    Archambault GF
    Hosp Formul; 1976 Dec; 11(12):690. PubMed ID: 1028797
    [No Abstract]   [Full Text] [Related]  

  • 80. Selected item from the FDA drug bulletin. Use of drugs for unapproved indications: legal responsibility.
    Calif Med; 1972 Dec; 117(6):80-1. PubMed ID: 4635407
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.